Alnylam Confident It Won’t Stumble On ATTR Trial Like BridgeBio

Aiming To Challenge Pfizer In Cardiomyopathy

Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.

Alnylam building — Alnylam is depending on the trial to expand into treating ATTR cardiomyopathy patients. • Source: Alamy

Alnylam is awaiting a pivotal trial readout from Onpattro (patisiran) which should help extend its presence in rare disease transthyretin amyloidosis (ATTR), but analysts are wary after the failure of a similar study by a competitor.

Last month BridgeBio Pharma’s candidate acoramidis failed to show improvements in ATTR patients with heart condition amyloid cardiomyopathy (ATTR-CM)...